

E Anders Kolb

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8548077/publications.pdf>

Version: 2024-02-01

176
papers

7,215
citations

57719

44
h-index

71651

76
g-index

182
all docs

182
docs citations

182
times ranked

8765
citing authors

#	ARTICLE	IF	CITATIONS
1	The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. <i>Nature Medicine</i> , 2018, 24, 103-112.	15.2	525
2	The pediatric preclinical testing program: Description of models and early testing results. <i>Pediatric Blood and Cancer</i> , 2007, 49, 928-940.	0.8	430
3	Dickkopf 3 Inhibits Invasion and Motility of Saos-2 Osteosarcoma Cells by Modulating the Wnt- β -Catenin Pathway. <i>Cancer Research</i> , 2004, 64, 2734-2739.	0.4	255
4	Initial testing of the aurora kinase a inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). <i>Pediatric Blood and Cancer</i> , 2010, 55, 26-34.	0.8	195
5	Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF β 1 receptor by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2008, 50, 1190-1197.	0.8	168
6	Long-Term Event-Free Survival After Intensive Chemotherapy for Ewing's Family of Tumors in Children and Young Adults. <i>Journal of Clinical Oncology</i> , 2003, 21, 3423-3430.	0.8	167
7	Parallel Randomized Trials of Risk-Based Therapy for Fetal Alloimmune Thrombocytopenia. <i>Obstetrics and Gynecology</i> , 2006, 107, 91-96.	1.2	165
8	Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2008, 50, 799-805.	0.8	162
9	MicroRNAs and Potential Targets in Osteosarcoma: Review. <i>Frontiers in Pediatrics</i> , 2015, 3, 69.	0.9	141
10	Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2008, 50, 581-587.	0.8	116
11	Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2008, 50, 37-45.	0.8	112
12	Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Dyskeratosis Congenita. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1238-1243.	2.0	108
13	Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design. <i>Cell Reports</i> , 2019, 29, 1675-1689.e9.	2.9	103
14	Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program. <i>Clinical Cancer Research</i> , 2015, 21, 819-832.	3.2	100
15	Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma. <i>Cancer</i> , 2003, 98, 832-840.	2.0	97
16	Initial testing (stage 1) of AZD6244 (ARRY-42886) by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2010, 55, 668-677.	0.8	94
17	Initial testing of a monoclonal antibody (IMC-A12) against IGF β 1R by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2010, 54, 921-926.	0.8	89
18	Stage 2 Combination Testing of Rapamycin with Cytotoxic Agents by the Pediatric Preclinical Testing Program. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 101-112.	1.9	89

#	ARTICLE	IF	CITATIONS
19	Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2008, 51, 42-48.	0.8	88
20	Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 1291-1304.	1.1	88
21	Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children's Oncology Group. <i>Haematologica</i> , 2020, 105, 1879-1886.	1.7	83
22	Intracranial hemorrhage in alloimmune thrombocytopenia: stratified management to prevent recurrence in the subsequent affected fetus. <i>American Journal of Obstetrics and Gynecology</i> , 2010, 203, 135.e1-135.e14.	0.7	81
23	Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2013, 60, 1325-1332.	0.8	77
24	Ecteinascidin-743 inhibits activated but not constitutive transcription. <i>Cancer Research</i> , 2002, 62, 3377-81.	0.4	77
25	Initial testing (stage 1) of LCL161, a SMAC mimetic, by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2012, 58, 636-639.	0.8	73
26	Delivery of care consistent with the psychosocial standards in pediatric cancer: Current practices in the United States. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26869.	0.8	73
27	Inhibition of Src Phosphorylation Alters Metastatic Potential of Osteosarcoma <i>In vitro</i> but not <i>In vivo</i> . <i>Clinical Cancer Research</i> , 2009, 15, 3416-3422.	3.2	70
28	Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2010, 55, 295-303.	0.8	70
29	Initial testing of dasatinib by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2008, 50, 1198-1206.	0.8	69
30	Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia. <i>Leukemia</i> , 2019, 33, 1934-1943.	3.3	69
31	R1507, a fully human monoclonal antibody targeting IGF1R, is effective alone and in combination with rapamycin in inhibiting growth of osteosarcoma xenografts. <i>Pediatric Blood and Cancer</i> , 2010, 55, 67-75.	0.8	67
32	Initial testing (stage 1) of the IGF1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2011, 56, 595-603.	0.8	67
33	Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional <i>in vivo</i> response to BMN 673. <i>Pediatric Blood and Cancer</i> , 2015, 62, 91-98.	0.8	65
34	Implementing the psychosocial standards in pediatric cancer: Current staffing and services available. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26634.	0.8	62
35	Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models. <i>Clinical Cancer Research</i> , 2019, 25, 2278-2289.	3.2	57
36	Initial testing of the MDM2 inhibitor RG7112 by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2013, 60, 633-641.	0.8	55

#	ARTICLE	IF	CITATIONS
37	The B7-H3 Targeting Antibody-Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models. <i>Clinical Cancer Research</i> , 2021, 27, 2938-2946.	3.2	55
38	CEBPA-bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children's Oncology Group. <i>Blood</i> , 2021, 138, 1137-1147.	0.6	55
39	Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2009, 53, 505-508.	0.8	54
40	The Folate Receptor Is Frequently Overexpressed in Osteosarcoma Samples and Plays a Role in the Uptake of the Physiologic Substrate 5-Methyltetrahydrofolate. <i>Clinical Cancer Research</i> , 2007, 13, 2557-2567.	3.2	52
41	Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis. <i>Cancer Research</i> , 2016, 76, 5798-5809.	0.4	52
42	Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2010, 55, 1126-1133.	0.8	51
43	Management of chronic myeloid leukemia in children and adolescents: Recommendations from the Children's Oncology Group CML Working Group. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27827.	0.8	50
44	CSF3R mutations have a high degree of overlap with CEBPA mutations in pediatric AML. <i>Blood</i> , 2016, 127, 3094-3098.	0.6	49
45	MicroRNA Expression-Based Model Indicates Event-Free Survival in Pediatric Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2017, 35, 3964-3977.	0.8	49
46	Development of IGF-IR inhibitors in pediatric sarcomas. <i>Current Oncology Reports</i> , 2009, 11, 307-313.	1.8	48
47	A Review of Targeted Therapies Evaluated by the Pediatric Preclinical Testing Program for Osteosarcoma. <i>Frontiers in Oncology</i> , 2013, 3, 132.	1.3	48
48	A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra-cranial solid tumors: A Children's Oncology Group Phase I Consortium report. <i>Pediatric Blood and Cancer</i> , 2015, 62, 751-758.	0.8	47
49	Initial testing (stage 1) of the polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program. <i>Pediatric Blood and Cancer</i> , 2014, 61, 158-164.	0.8	46
50	Targeting Glycoprotein NMB With Antibody-Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma. <i>Pediatric Blood and Cancer</i> , 2016, 63, 32-38.	0.8	46
51	Combination testing (Stage 2) of the Anti-IGF1 receptor antibody IMC-A12 with rapamycin by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2012, 58, 729-735.	0.8	44
52	Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2010, 55, 1329-1337.	0.8	43
53	Comprehensive Transcriptome Profiling of Cryptic CBFA2T3-GLIS2 Fusion Positive AML Defines Novel Therapeutic Options: A COG and TARGET Pediatric AML Study. <i>Clinical Cancer Research</i> , 2020, 26, 726-737.	3.2	42
54	Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2009, 53, 1255-1263.	0.8	40

#	ARTICLE	IF	CITATIONS
55	Systemic administration of reovirus (Reolysin) inhibits growth of human sarcoma xenografts. <i>Cancer</i> , 2011, 117, 1764-1774.	2.0	40
56	Effect of Dexrazoxane on Left Ventricular Systolic Function and Treatment Outcomes in Patients With Acute Myeloid Leukemia: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2020, 38, 2398-2406.	0.8	40
57	Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric <i>KMT2A</i> -Rearranged AML: Results From the Phase III Children's Oncology Group Trial AAML0531. <i>Journal of Clinical Oncology</i> , 2021, 39, 3149-3160.	0.8	40
58	Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2012, 58, 916-923.	0.8	39
59	Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2012, 59, 1266-1274.	0.8	38
60	Insulin-Like Growth Factor 1 Receptor and Response to Anti-IGF1R Antibody Therapy in Osteosarcoma. <i>PLoS ONE</i> , 2014, 9, e106249.	1.1	38
61	Imatinib mesylate in Philadelphia chromosome-positive leukemia of childhood. <i>Cancer</i> , 2003, 98, 2643-2650.	2.0	37
62	Initial testing of topotecan by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2010, 54, 707-715.	0.8	37
63	Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program. <i>Pediatric Blood and Cancer</i> , 2014, 61, 245-252.	0.8	37
64	Testing of the Akt/PKB inhibitor MK-2206 by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2012, 59, 518-524.	0.8	36
65	Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio <i>FLT3</i> /ITD+ Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML1031. <i>Journal of Clinical Oncology</i> , 2022, 40, 2023-2035.	0.8	36
66	Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2012, 58, 191-199.	0.8	35
67	Initial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1816-1821.	0.8	35
68	Phase I/II Study of CPX-351 Followed by Fludarabine, Cytarabine, and Granulocyte-Colony Stimulating Factor for Children With Relapsed Acute Myeloid Leukemia: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2020, 38, 2170-2177.	0.8	35
69	Vorinostat Enhances Cytotoxicity of SN-38 and Temozolomide in Ewing Sarcoma Cells and Activates STAT3/AKT/MAPK Pathways. <i>PLoS ONE</i> , 2015, 10, e0142704.	1.1	34
70	Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG), Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.8	31
71	Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2011, 57, 443-453.	0.8	31
72	Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a β -secretase inhibitor targeting notch signaling. <i>Pediatric Blood and Cancer</i> , 2012, 58, 815-818.	0.8	31

#	ARTICLE	IF	CITATIONS
73	Initial testing of cisplatin by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2008, 50, 992-1000.	0.8	30
74	Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2012, 59, 246-253.	0.8	30
75	Survival Following Relapse in Children with Acute Myeloid Leukemia: A Report from AML-BFM and COG. <i>Cancers</i> , 2021, 13, 2336.	1.7	30
76	Initial testing (stage 1) of the tubulin binding agent nanoparticle albumin-bound (nab) paclitaxel (Abraxane [®]) by the Pediatric Preclinical Testing Program (PPTP). <i>Pediatric Blood and Cancer</i> , 2015, 62, 1214-1221.	0.8	29
77	Preclinical activity of palifosfamide lysine (ZIO-201) in pediatric sarcomas including oxazaphosphorine-resistant osteosarcoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 733-740.	1.1	28
78	Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2009, 53, 594-598.	0.8	28
79	Xenograft and genetically engineered mouse model systems of osteosarcoma and Ewing's sarcoma: tumor models for cancer drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2013, 8, 1181-1189.	2.5	28
80	Acute myeloid leukemia in children and adolescents: identification of new molecular targets brings promise of new therapies. <i>Hematology American Society of Hematology Education Program</i> , 2015, 2015, 507-513.	0.9	28
81	Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2016, 63, 276-286.	0.8	28
82	Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2013, 60, 1860-1867.	0.8	27
83	Initial Testing (Stage 1) of MK-8242 "A Novel MDM2 Inhibitor" by the Pediatric Preclinical Testing Program. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1744-1752.	0.8	27
84	Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2012, 58, 566-571.	0.8	26
85	Distinct age-associated molecular profiles in acute myeloid leukemia defined by comprehensive clinical genomic profiling. <i>Oncotarget</i> , 2018, 9, 26417-26430.	0.8	25
86	Targeted inhibitors and antibody immunotherapies: Novel therapies for paediatric leukaemia and lymphoma. <i>European Journal of Cancer</i> , 2022, 164, 1-17.	1.3	24
87	Disruption of Annexin II /p11 Interaction Suppresses Leukemia Cell Binding, Homing and Engraftment, and Sensitizes the Leukemia Cells to Chemotherapy. <i>PLoS ONE</i> , 2015, 10, e0140564.	1.1	23
88	Preclinical Analysis of Tasidotin HCl in Ewing's Sarcoma, Rhabdomyosarcoma, Synovial Sarcoma, and Osteosarcoma. <i>Clinical Cancer Research</i> , 2007, 13, 5446-5454.	3.2	22
89	Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2012, 59, 329-332.	0.8	22
90	Generation of Pediatric Leukemia Xenograft Models in NSG-B2m Mice: Comparison with NOD/SCID Mice. <i>Frontiers in Oncology</i> , 2016, 6, 162.	1.3	21

#	ARTICLE	IF	CITATIONS
91	Disease Characteristics and Prognostic Implications of Cell-Surface FLT3 Receptor (CD135) Expression in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group. <i>Clinical Cancer Research</i> , 2017, 23, 3649-3656.	3.2	21
92	Morphologic remission status is limited compared to \hat{I}^N flow cytometry: a Children's Oncology Group AAML0531 report. <i>Blood Advances</i> , 2020, 4, 5050-5061.	2.5	21
93	Initial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2012, 59, 749-752.	0.8	20
94	Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing Program. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26304.	0.8	20
95	Mesothelin: An Immunotherapeutic Target beyond Solid Tumors. <i>Cancers</i> , 2022, 14, 1550.	1.7	20
96	Successful outcome with tandem myeloablative chemotherapy and autologous peripheral blood stem cell transplants in a patient with atypical teratoid/rhabdoid tumor of the central nervous system. <i>Journal of Neuro-Oncology</i> , 2008, 88, 211-215.	1.4	19
97	Initial testing (stage 1) of the phosphatidylinositol 3 \hat{a} ² kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2013, 60, 791-798.	0.8	19
98	Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1486-1489.	0.8	19
99	Screening for Family Psychosocial Risk in Pediatric Hematopoietic Stem Cell Transplantation with the Psychosocial Assessment Tool. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1374-1381.	2.0	19
100	A phase II study of eribulin in recurrent or refractory osteosarcoma: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27524.	0.8	19
101	Discovery and Functional Validation of Novel Pediatric Specific FLT3 Activating Mutations in Acute Myeloid Leukemia: Results from the COG/NCI Target Initiative. <i>Blood</i> , 2015, 126, 87-87.	0.6	19
102	Initial testing (stage 1) of the polyamine analog PG11047 by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2011, 57, 268-274.	0.8	18
103	CD123 Expression Is Associated With High-Risk Disease Characteristics in Childhood Acute Myeloid Leukemia: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2022, 40, 252-261.	0.8	18
104	Testing of the topoisomerase 1 inhibitor Genz-644282 by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2012, 58, 200-209.	0.8	16
105	Risk factors for chemotherapy-induced nausea in pediatric patients receiving highly emetogenic chemotherapy. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27584.	0.8	16
106	CD81 knockout promotes chemosensitivity and disrupts in vivo homing and engraftment in acute lymphoblastic leukemia. <i>Blood Advances</i> , 2020, 4, 4393-4405.	2.5	16
107	Mesothelin is a novel cell surface disease marker and potential therapeutic target in acute myeloid leukemia. <i>Blood Advances</i> , 2021, 5, 2350-2361.	2.5	16
108	High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trial. <i>Blood</i> , 2021, 138, 2337-2346.	0.6	16

#	ARTICLE	IF	CITATIONS
109	Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26263.	0.8	15
110	Acupressure bands do not improve chemotherapy-induced nausea control in pediatric patients receiving highly emetogenic chemotherapy: A single-blind, randomized controlled trial. <i>Cancer</i> , 2018, 124, 1188-1196.	2.0	15
111	Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2012, 59, 185-188.	0.8	14
112	Initial testing (stage 1) of the anti-microtubule agents cabazitaxel and docetaxel, by the Pediatric Preclinical Testing Program. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1897-1905.	0.8	14
113	Error-corrected sequencing strategies enable comprehensive detection of leukemic mutations relevant for diagnosis and minimal residual disease monitoring. <i>BMC Medical Genomics</i> , 2020, 13, 32.	0.7	14
114	The Combination of Clofarabine and Cytarabine in Pediatric Relapsed Acute Lymphoblastic Leukemia: A Case Report. <i>Chemotherapy</i> , 2008, 54, 120-124.	0.8	13
115	Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2010, 54, 307-310.	0.8	13
116	Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2013, 60, 783-790.	0.8	13
117	Epigenetic drug combination induces remission in mouse xenograft models of pediatric acute myeloid leukemia. <i>Leukemia Research</i> , 2017, 58, 91-97.	0.4	13
118	Development of a Novel Next-Generation Sequencing Assay for Carrier Screening in Old Order Amish and Mennonite Populations of Pennsylvania. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 687-694.	1.2	13
119	Preclinical evaluation of the combination of AZD1775 and irinotecan against selected pediatric solid tumors: A Pediatric Preclinical Testing Consortium report. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28098.	0.8	13
120	Comprehensive Surfaceome Profiling to Identify and Validate Novel Cell-Surface Targets in Osteosarcoma. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 903-913.	1.9	12
121	Hematopoietic Cell Transplantation in the Treatment of Pediatric Acute Myelogenous Leukemia and Myelodysplastic Syndromes: Guidelines from the American Society of Transplantation and Cellular Therapy. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 530-545.	0.6	12
122	Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2013, 60, E42-5.	0.8	11
123	Initial testing of aplidin by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2009, 53, 509-512.	0.8	10
124	Heat shock factor 1 (HSF1-pSer326) predicts response to bortezomib-containing chemotherapy in pediatric AML: a COG report. <i>Blood</i> , 2021, 137, 1050-1060.	0.6	10
125	Second Relapse of Pediatric Patients with Acute Myeloid Leukemia: A Report on Current Treatment Strategies and Outcome of the AML-BFM Study Group. <i>Cancers</i> , 2021, 13, 789.	1.7	10
126	The Addition of Bortezomib to Standard Chemotherapy for Pediatric Acute Myeloid Leukemia Has Increased Toxicity without Therapeutic Benefit: A Report from the Children's Oncology Group. <i>Blood</i> , 2016, 128, 899-899.	0.6	10

#	ARTICLE	IF	CITATIONS
127	Progress of oncolytic viruses in sarcomas. Expert Review of Anticancer Therapy, 2012, 12, 229-242.	1.1	9
128	Oncolytic Viruses for Potential Osteosarcoma Therapy. Advances in Experimental Medicine and Biology, 2014, 804, 259-283.	0.8	9
129	Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2015, 62, 1106-1109.	0.8	9
130	Dose-response effect of eribulin in preclinical models of osteosarcoma by the pediatric preclinical testing consortium. Pediatric Blood and Cancer, 2020, 67, e28606.	0.8	9
131	A Phase 2 Trial of KIR-Mismatched Unrelated Donor Transplantation Using in Vivo T Cell Depletion with Antithymocyte Globulin in Acute Myelogenous Leukemia: Children's Oncology Group AAML05P1 Study. Biology of Blood and Marrow Transplantation, 2020, 26, 712-717.	2.0	8
132	Stability and change in family psychosocial risk over 6 months in pediatric cancer and its association with medical and psychosocial healthcare utilization. Pediatric Blood and Cancer, 2020, 67, e28051.	0.8	8
133	Modeling Transient Abnormal Myelopoiesis Using Induced Pluripotent Stem Cells and CRISPR/Cas9 Technology. Molecular Therapy - Methods and Clinical Development, 2020, 19, 201-209.	1.8	8
134	Initial in vivo testing of a multitarget kinase inhibitor, regorafenib, by the Pediatric Preclinical Testing Consortium. Pediatric Blood and Cancer, 2020, 67, e28222.	0.8	8
135	Initial solid tumor testing (Stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2014, 61, 1972-1979.	0.8	7
136	Cytotoxicity of Zardaverine in Embryonal Rhabdomyosarcoma from a Costello Syndrome Patient. Frontiers in Oncology, 2017, 7, 42.	1.3	7
137	Mentors™ perspectives on the successes and challenges of mentoring in the COG Young Investigator mentorship program: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2019, 66, e27920.	0.8	7
138	Polygenic Ara-C Response Score Identifies Pediatric Patients With Acute Myeloid Leukemia in Need of Chemotherapy Augmentation. Journal of Clinical Oncology, 2022, 40, 772-783.	0.8	7
139	Initial testing (stage 1) of the notch inhibitor PF03084014, by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2014, 61, 1493-1496.	0.8	6
140	CRISPR/Cas9-Directed Reassignment of the GATA1 Initiation Codon in K562 Cells to Recapitulate AML in Down Syndrome. Molecular Therapy - Nucleic Acids, 2017, 7, 288-298.	2.3	6
141	Development of acute lymphoblastic leukemia following treatment for acute myeloid leukemia in children with Down syndrome: A case report and retrospective review of Children's Oncology Group acute myeloid leukemia trials. Pediatric Blood and Cancer, 2019, 66, e27700.	0.8	6
142	Initial <i>in vivo</i> testing of TPO-receptor agonist eltrombopag in osteosarcoma patient-derived xenograft models by the pediatric preclinical testing consortium. Pediatric Hematology and Oncology, 2021, 38, 8-13.	0.3	6
143	Correlation of CD123 Expression Level with Disease Characteristics and Outcomes in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group. Blood, 2019, 134, 459-459.	0.6	6
144	Response to Sorafenib in FLT3/ITD AML Is Dependent on Co-Occurring Mutational Profile. Blood, 2019, 134, 119-119.	0.6	6

#	ARTICLE	IF	CITATIONS
145	Outcomes of intensification of induction chemotherapy for children with high-risk acute myeloid leukemia: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29281.	0.8	6
146	Initial testing (Stage 1) of TAK-701, a humanized hepatocyte growth factor binding antibody, by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2014, 61, 380-382.	0.8	5
147	Cytarabine dose reduction in patients with low-risk acute myeloid leukemia: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29313.	0.8	5
148	Immunotherapeutic Targeting of Mesothelin in Acute Myeloid Leukemia in Vitro with Anetumab Ravtansine and a Novel Antibody-Drug Conjugate. <i>Blood</i> , 2018, 132, 1448-1448.	0.6	5
149	Imetelstat Induces Leukemia Stem Cell Death in Pediatric Acute Myeloid Leukemia Patient-Derived Xenografts. <i>Journal of Clinical Medicine</i> , 2022, 11, 1923.	1.0	5
150	Initial testing of lenalidomide by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2011, 57, 606-611.	0.8	4
151	Down syndrome and AML: where do we go from here?. <i>Blood</i> , 2017, 129, 3274-3275.	0.6	4
152	A psychosocial clinical care pathway for pediatric hematopoietic stem cell transplantation. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27889.	0.8	4
153	A 3-D hydrogel based system for hematopoietic differentiation and its use in modeling down syndrome associated transient myeloproliferative disorder. <i>Biomaterials Science</i> , 2021, 9, 6266-6281.	2.6	4
154	Bortezomib is significantly beneficial for de novo pediatric AML patients with low phosphorylation of the NF- κ B subunit RelA. <i>Proteomics - Clinical Applications</i> , 2021, , 2100072.	0.8	4
155	Blood Count Recovery Following Induction Therapy for Acute Myeloid Leukemia in Children Does Not Predict Survival. <i>Cancers</i> , 2022, 14, 616.	1.7	4
156	Opportunities for expanding clinical trial enrollment for relapsed and refractory pediatric acute myeloid leukemia in the United States and Canada. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26632.	0.8	3
157	Bone marrow transplant and pediatric multiple myeloma. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27528.	0.8	3
158	Results of a phase 2, multicenter, single-arm, open-label study of lenalidomide in pediatric patients with relapsed or refractory acute myeloid leukemia. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28946.	0.8	3
159	Comprehensive Transcriptome Profiling of Cryptic CBFA2T3-GLIS2 Fusion-Positive AML Defines Novel Therapeutic Options – a COG and Target Pediatric AML Study. <i>Blood</i> , 2018, 132, 881-881.	0.6	3
160	Efficacy of Flotetuzumab in Combination with Cytarabine in Patient-Derived Xenograft Models of Pediatric Acute Myeloid Leukemia. <i>Journal of Clinical Medicine</i> , 2022, 11, 1333.	1.0	3
161	Testing of B7-H3 targeting antibody-drug conjugate (ADC) MGC018 in models of pediatric solid tumors by the Pediatric Preclinical Testing Consortium (PPTC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 10037-10037.	0.8	2
162	Comprehensive Sequence Analysis of Relapse and Refractory Pediatric Acute Myeloid Leukemia Identifies miRNA and mRNA Transcripts Associated with Treatment Resistance - a Report from the COG/NCI-Target AML Initiative. <i>Blood</i> , 2015, 126, 687-687.	0.6	2

#	ARTICLE	IF	CITATIONS
163	Evaluation of the multi-kinase inhibitor regorafenib in the Pediatric Preclinical Testing Consortium osteosarcoma, rhabdomyosarcoma, and Ewing sarcoma in vivo models.. Journal of Clinical Oncology, 2019, 37, 10038-10038.	0.8	2
164	Strong concordance between RNA structural and single nucleotide variants identified via next generation sequencing techniques in primary pediatric leukemia and patient-derived xenograft samples. Genomics and Informatics, 2020, 18, e6.	0.4	2
165	Immunotherapeutic Targeting of Mesothelin Positive Pediatric AML Using Bispecific T Cell Engaging Antibodies. Cancers, 2021, 13, 5964.	1.7	2
166	Physician risk perceptions and surveillance practices for tyrosine kinase inhibitor long-term effects in pediatric CML. Pediatric Hematology and Oncology, 2022, 39, 453-467.	0.3	2
167	Moving towards non-invasive assessments of prognosis in osteosarcoma. Pediatric Blood and Cancer, 2010, 54, 497-498.	0.8	1
168	Aggressive Hematopoietic Malignancy Characterized by Biallelic Loss of SMARCB1. JCO Precision Oncology, 2020, 4, 1280-1284.	1.5	1
169	Abstract LB-213: Combination of epigenetic modifiers achieves complete remission in xenograft models of pediatric acute myeloid leukemia. , 2015, , .		1
170	Enhancement of Eligibility Guidelines for Gemtuzumab Ozogamicin Therapy for Childhood Acute Myeloid Leukemia: A Report from Children's Oncology Group Protocol AAML0531. Blood, 2018, 132, 1490-1490.	0.6	1
171	Newly Diagnosed Childhood AML Patients Treated with Bortezomib Show Superior Survival If CD74 Is Expressed: A Report of 991 Patients from the Children's Oncology Group AAML1031 Protocol. Blood, 2020, 136, 39-39.	0.6	1
172	Modeling Down Syndrome Myeloid Leukemia by Sequential Introduction of GATA1 and STAG2 Mutations in Induced Pluripotent Stem Cells with Trisomy 21. Cells, 2022, 11, 628.	1.8	1
173	Challenges in Converting Acute Myeloid Leukemia (AML) Genomics Into AML Clinical Trials. Journal of Clinical Oncology, 2015, 33, 4238-4239.	0.8	0
174	Initial Testing of NSC 750854, a Novel Purine Analog, Against Pediatric Tumor Models by the Pediatric Preclinical Testing Program. Pediatric Blood and Cancer, 2016, 63, 443-450.	0.8	0
175	Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design. SSRN Electronic Journal, 0, , .	0.4	0
176	Evaluation of the TPO-receptor agonist Eltrombopag in the Pediatric Preclinical Testing Consortium osteosarcoma in vivo models.. Journal of Clinical Oncology, 2019, 37, e22502-e22502.	0.8	0